The platform gives scientists more access to more data and new tools
Seattle, November 17, 2020 / PRNewswire / – Launching today is the Alzheimer’s Disease Data Initiative (ADDI) and its Alzheimer’s disease (AD) Scope of work, A cloud-based platform for scientists to accelerate discoveries and innovations for AD and related dementias. ADDI is a new global effort aimed at linking data to generate insights to researchers and advancing AD innovation to inform the development of advanced treatments and diagnostic tools. ADDI, a 501 (c) (3) medical research organization, was created by a coalition of partners, which provides new ways to enhance the partnership of dementia-related data among researchers and to experiment with the most reliable datasets.
For decades, scientists have made limited progress in Alzheimer’s research and medical science, even though Alzheimer’s is a leading cause of death worldwide, estimated to cost more than care $ 1 trillion Yearly. Now more than ever, more and more data sharing is needed to spew innovative discoveries in AD research. Advancement is possible — limited access to data should not be an obstacle.
The idea for ADDI was launched after 2018. Bill Gates A coalition of partners interested in advertising and related dementia data sharing were brought together with the aim of moving faster towards better innovation and diagnostic tools.
“There has never been a need for new and more effective treatments for Alzheimer’s disease. A better understanding of the disease will help us detect and diagnose it earlier. People should be easy to find, enroll, and live in clinical trials, and we should accelerate the pace of discovery and innovation. Data can play a key role in successes, ”said Bill Gates. “Data is a powerful tool that can be better exploited to understand and mitigate the effects of AD. It’s AD Scope of work Is designed to do. “
Eddy. Scope of work Will facilitate interoperability across data platforms and enable researchers to work with multiple datasets. AD with a federated model of data sharing Scope of work Permitted allows researchers to transfer data from their dataset, access and other platforms. This allows them to work safely with anonymous datasets that are unable to be transferred due to data privacy, regulation, and local laws. Within the platform, users have an individual workspace where they can ensure quality control, consistency of data and analysis of data within the platform. Soon A.D. Scope of work Will provide researchers and data scientists the ability to share code and crowdsource ideas.
“There is no limit to the innovation that can arise from researchers working together with more data than ever before,” said the executive director of ADDI. Tetsu Maruyama. “That’s what makes Scope of work So exciting – and this is just the beginning. Scope of work Will continue to develop with input and data from the research community, allowing scientists to work with new tools and more data. “
The scope will increase access to many types of data that will both progress towards our basic understanding of ED and related dementia and their treatment:
- Allowing scientists to combine data from multiple studies to strengthen understanding beyond what can be learned from a single study;
- Enabling researchers to revisit existing datasets with new analytical methods and technologies; And
- Accelerating future research by breaking traditional research barriers.
“Data sharing has tremendous power and the ability to harmonize data across multiple groups,” Dr. Risa Spurling, Director, Alzheimer’s Research and Treatment Center, Brigham and Women’s Hospital. “Eddy. Scope of work New methods will make it easier to access and discover data and expand collaboration opportunities. ”
ADDI will foster an environment that supports and facilitates researchers’ abilities to share data by providing resources. Also A.D. Scope of work, ADDI has collided existing tools and created new tools that will help researchers navigate regulatory frameworks and policies that are often barriers to data sharing. ADDI will fund researchers and organizations who wish to expand data access and sharing using AD Scope of work. Increasing access to the best and most reliable datasets is one of the most effective ways to accelerate progress towards more effective treatments, and diagnoses that can help clinicians and dementia people. Together, these successes will significantly reduce the impact of AD on patients, their families, and the health system.
for more information please visit:
The Alzheimer’s Disease Data Initiative (ADDI), a 501 (c) (3) Medical Research Organization (MRO) in partnership with the University of Washington, is dedicated to advancing scientific breakthroughs in the treatment of Alzheimer’s disease and related dementia. ADDI aims to increase the interoperability of existing data platforms globally, increase the sharing of dementia-related data from academic and industry sources, and allow scientists to discover, discover, combine, and analyze data that is important in dementia research Could lead to new discoveries. The purpose of ADDI also involves increasing or filling gaps in data sets, including enabling the generation of demographically representative datasets.
LinkedIn: AlzheimersData Twitter: AlzData
The alliance of partners of ADDI includes AARP, Aridhia, Alzheimer’s Association, Alzheimer’s Research UK, Biogen, Bezos Expedition, Alzheimer’s Disease (CPAD) Consortium, Dementia Platform UK (DPUK), Fidelity Biomedical Research Initiative (FBRI), GTA, Vent. Global Alzheimer’s Association Interactive Network (GAAIN), Medical Research Council UK, National Institutes of Health / National Institutes on Aging, VOR AI and Welcome Trust.
Logo – https://themiracletech.com/wp-content/uploads/2020/11/The-Alzheimers-Disease-Data-Initiative-launches-new-advertising-verticals-to.jpg
Content is by PR Newswire. Tech Media is not responsible for the content provided or any link related to this content. Tech Media is not responsible for the accuracy, timeliness or quality of content.